KC02 is a structural analog of KC01 and inactive form of KC01.
The synthesis of KC02 consistently yielded a 4:1 mixture of Z/E isomers, which proved difficult to chromatographically separate. By competitive gel-based ABPP assys, KC02 inhibited ABHD16A (human and mouse) with IC50 value of >10μM, while KC01 is in range of nM. By PS substrate assays, KC02 inhibited human ABHD16A with IC50 value of > 10μM, while KC01 is in range of nM.
Most of these enzymes were also inhibited by the control probe KC02, with the exception of two partial off-targets, ABHD3 and ABHD13. KC02 also inhibited ABHD11 (94%) and LYPLA1 (63%) but did not substantially inhibit ABHD16A (<30%). In situ treatment with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h) blocked the PS lipase activity of membrane fractions from COLO205, K562 and MCF7 cell lines. KC01 and KC02 constitute a suitable pair of active and inactive (control) probes to investigate the function of ABHD16A in cellular systems. Treatment with KC01 but not KC02 (1μM, 4 h) substantially lowered secreted lyso-PSs of the ABHD12-null LCL. All LCLs also showed decreased cellular lyso-PSs following treatment with KC01 but not KC02. KC01 but not KC02 elevated PS lipase activity and reduced in lyso-PS lipase activity in LPS-stimulated macrophages. The LPS-induced increases in lyso-PS and cytokine secretion were both blocked by pretreatment of Abhd12−/− macrophages with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h).
In COLO205 cells, 1μM KC01 but not KC02 showed substantial reductions in the levels of all detected cellular lyso-PSs compared to DMSO-treated control cells. The levels of secreted lyso-PSs (18:1 and 18:0) were also decreased in COLO205 cells treated with KC01 compared to those in KC02- or DMSO-treated cells (4-h treatments of cells in serum-free medium), whereas levels of other secreted lipids (lyso-PCs, lyso-PEs and MAGs) were unchanged across these treatment groups.
KC01, but not KC02, inhibited the PS lipase activity of brain membrane lysates from 2-month-old Abhd12+/+ and Abhd12−/− mice.
Reference:
1.Kamat SS, Camara K2, Parsons WH et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol. 2015 Feb;11(2):164-71.
KC02
目录号: GC13023纯度: >98%
Structural analog and inactive form of KC01
Cas No.: 1646795-60-9
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 5mg | ¥9,093.00 | 现货 | 1 |
电话: 400-920-5774Email: sales@glpbio.cn
文献被引
本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
Nature641, 529–536 (2025)
Nature628, 630–638 (2024)
Nature632, 686–694 (2024)
Nature618, 1017–1023 (2023)
Nature610, 366–372 (2022)
Cell187(9):2288-2304 (2024)
Cell183(7):1867-1883 (2020)
Science388(6745) (2025)
Science387(6739) (2025)
Science387(6734) (2025)
Cell Research35, 97–116 (2025)
Cell Research34, 683–706 (2024)
Cell Research33, 273–287 (2023)
Cell Research33, 546–561 (2023)
Cell Research33, 904–922 (2023)
Cell Research31, 1291–1307 (2021)
产品描述 Description
产品文档 Product Documents
Purity:>98%
化学性质Chemical Properties
CAS 号
1646795-60-9
化学名
6-(2-oxo-4-tridecyloxetan-3-yl)hexanamide
SMILES
CCCCCCCCCCCCCC1OC(C1CCCCCC(N)=O)=O
分子式
C22H41NO3
分子量
367.57 g/mol
溶解性
DMF: 5 mg/ml,DMSO: 5 mg/ml,Ethanol: 16 mg/ml,Ethanol:PBS(pH 7.2) (1:5): 0.5 mg/ml
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。
计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度
g/mol
